The use of GLP-1 receptor agonists in hospitalised patients: an untapped potential

O.G.Mustafa¹, M.B.Whyte¹,²

1. Dept of Diabetes, King’s College Hospital NHS Foundation Trust
2. Dept of Clinical & Experimental Medicine, University of Surrey

Address for correspondence
Dr. Martin Whyte, Diabetes and Metabolic Medicine, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford, UK, GU2 7WG

Email: m.b.whyte@surrey.ac.uk
Phone: +44 1483 68 8669
Word count: 3310
Keywords: acute illness, perioperative, inpatient, GLP-1

Conflict of Interest statement: MBW has received research funding from Eli Lilly and Sanofi, speaker fees from Astra Zeneca and Merck Sharp & Dohme (MSD) and Consulting fee from Boehringer-Ingelheim. OM has no conflict of interest.

Funding: No funding was received for this article.
Abstract

In the outpatient setting, Glucagon-like peptide-1 (GLP-1) receptor agonists have proved to be highly efficacious drugs that provide glycaemic control with a low risk of hypoglycaemia. These characteristics make GLP-1 receptor agonists attractive agents to treat dysglycaemia in perioperative or high-dependency hospital settings; where glycaemic variability and hyperglycaemia are associated with poor prognosis. GLP-1 also has a direct action on the myocardium and vasculature - which may be advantageous in the immediate aftermath of a vascular insult. This is a narrative review of the work in this area.

The aim was to determine the populations of hospitalised patients being evaluated and the clinical and mechanistic end-points tested, with the institution of GLP-1 therapy in hospital.

We searched the PubMed, Embase, and Google scholar databases, combining the term ‘glucagon-like peptide 1’ OR ‘GLP-1’ OR ‘incretin’ OR ‘liraglutide’ OR ‘exenatide’ OR ‘lixisenatide’ OR ‘dulaglutide’ OR ‘albiglutide’ AND ‘inpatient’ OR ‘hospital’ OR ‘perioperative’ OR ‘postoperative’ OR ‘surgery’ OR ‘myocardial infarction’ OR ‘stroke’ OR ‘cerebrovascular disease’ OR ‘transient ischaemic attack’ OR ‘ICU’ OR ‘critical care’ OR ‘critical illness’ OR ‘CCU’ OR ‘coronary care unit’.

Pilot studies were reported in the fields of acute stroke, cardiac resuscitation, coronary care and perioperative care that showed advantages for GLP-1 therapy; with normalisation of glucose, lower glucose variability and lower risk of hypoglycaemia. Animal and human studies have reported improvements in myocardial performance when given acutely after vascular insult or surgery, but these have yet to be translated into randomised clinical trials.
INTRODUCTION

In the outpatient setting, GLP-1 receptor agonists (GLP-1 RA) are considered to provide effective glycaemic control, weight loss and cardiovascular benefits with a low risk of hypoglycaemia \(^1\)\(^2\). The use of GLP-1 RA have increased rapidly and are now recommended for use as second-line therapy for Type 2 Diabetes (T2DM) \(^3\). As a result, individuals treated with GLP-1 RA will be more frequently encountered at the in-patient setting. Existing clinical guidelines for inpatient diabetes control only briefly discuss their role, if at all \(^4\)\(^-\)\(^6\).

Furthermore, the therapeutic benefit for GLP-1 RA is being tested in a range of acute clinical settings including perioperative, coronary care and critical care \(^7\)\(^-\)\(^15\). This narrative review will outline the inpatient clinical areas in which GLP-1 RA are being tested, the panoply of actions of GLP-1 that offer the potential for benefit in acute illness, and the outcome measures reported so far. This review will not encompass the effectiveness for GLP-1 RA to reduce hospitalisation or mortality from macrovascular disease (such as heart failure) which has been covered extensively elsewhere \(^16\)\(^-\)\(^17\); nor will it assess the usefulness of initiating GLP-1 RA therapy in the months before surgery. GLP-1 RA have been used with some success for short-bowel syndrome \(^18\) but our analysis is restricted to the use of GLP-1 for acute illness, perioperative and critical care areas.

Search methodology

We conducted a comprehensive search in the English-language literature to identify all relevant studies, regardless of publication status or year of publication. We searched the PubMed, Embase, and Google scholar databases, combining the term ‘glucagon-like peptide 1’ OR ‘GLP-1’ OR ‘incretin’ OR ‘liraglutide’ OR ‘exenatide’ OR ‘lixisenatide’ OR ‘dulaglutide’ OR ‘albiglutide’ AND ‘inpatient’ OR ‘hospital’ OR ‘perioperative’ OR ‘postoperative’ OR ‘surgery’ OR ‘myocardial infarction’ OR ‘stroke’ OR ‘cerebrovascular
disease’ OR ‘transient ischaemic attack’ OR ‘ICU’ OR ‘critical care’ OR ‘critical illness’ OR ‘CCU’ OR ‘coronary care unit’. Studies could include early or late phase human trials and those using animal models. We searched the National Institutes of Health database (http://clinicaltrials.gov/) and the EU clinical trials register (www.clinicaltrialsregister.eu) for ongoing and unpublished trials. We applied backward and forward snowballing to identify further papers. The bibliographies of all included studies and pertinent reviews were scanned for additional references. If required, the corresponding author of an included study was contacted for information regarding unpublished trials or complementary information on their own trial(s). The last search was performed in August 2018.

**Stroke and brain injury**

GLP-1 RAs have certain properties that lend themselves to use in cerebrovascular disease: most obvious is the ability to normalise glucose with a low propensity to hypoglycaemia. Ischaemic stroke leads to a penumbra of neural tissue that is potentially salvageable. Hyperglycaemia is associated with worse clinical outcomes in stroke including: haemorrhagic transformation, extent of neurological disability and death. Of those presenting with ischaemic stroke, 30% have known diabetes, 20% are newly recognised to have diabetes and a further 30% have impaired fasting glucose or glucose tolerance. Therefore just 20% have normal glucose homeostasis. Significant consequences arise from dysglycaemia: this may be due to the production of the excitatory neurotransmitter glutamate, or to reactive oxygen species which adversely affect the ischaemic penumbra. However, clinical trials in acute stroke have failed to show a clinical benefit from the amelioration of hyperglycaemia with insulin in the first 24-48 hours. Neurological gains from the avoidance of hyperglycaemia are mitigated by hypoglycaemia from the use of insulin. Hypoglycaemia is associated with increased markers of cerebral cellular distress including: elevated glutamate:
lactate/pyruvate ratio: and glycerol - which may themselves contribute to disability and death.

There is therefore a J-shaped association between plasma glucose and outcome after stroke. GLP-1 RAs offer the possibility of normalising glucose without hypoglycaemia. In a pilot study of 11 patients with acute ischaemic stroke, subcutaneous exenatide (for a median of six-days) restricted the incidence of hyperglycaemia (> 8.6mmol/L) to less than 5%, with no hypoglycaemia. Of note, nausea and vomiting occurred in half the cohort, which may prove to be a limiting factor in future studies. A large phase 2 trial is underway: the Trial of Exenatide in Acute Ischaemic Stroke (TEXAIS) is a three year, multi-centre, open label randomised controlled trial (RCT) comparing exenatide to standard care. It aims to recruit 528 patients with a clinically meaningful primary end-point of major neurological improvement at seven days.

Exendin-4 is a 39 amino acid peptide originally isolated from the oral secretions of the Gila monster lizard. It shares 53% sequence homology with GLP-1 and has been used in a number of pre-clinical studies. Murine studies of ischaemic brain damage using Exendin-4 and liraglutide show that they are capable of crossing the blood-brain barrier to act directly on the brain to produce neuroprotective and anti-inflammatory effects. The neuroprotective properties that GLP-1 RAs have shown in animal studies has also led to their evaluation in patients with brain injury after cardiac arrest. A dual-centre study in Denmark has investigated the neuroprotective effects of exenatide administered within four hours of the return of spontaneous circulation to comatose patients resuscitated from out-of-hospital cardiac arrest. The efficacy endpoint was the area under curve (AUC) from 0 to 72 hours after admission of neuron-specific enolase – a predictor of outcomes after cardiac arrest.

Although exenatide was effective in normalising blood glucose (median blood glucose eight hours after admission was 5.8 mmol/L vs 7.3 mmol/L, in placebo; \( P<0.0001 \)), exenatide did not reduce neuron-specific enolase levels and did not significantly improve a composite end-
point of death and poor neurological function after 180 days\textsuperscript{14}. Of note, exenatide was not administered until after the return of spontaneous circulation which could limit the effectiveness. More recently, a six-hour infusion of either 17.4 μg of exenatide or placebo, within four hours from sustained return of spontaneous circulation, showed that exenatide lowered glucose and increased the clearance of lactate (a surrogate marker for adequate tissue perfusion\textsuperscript{39}) by 21\% more than placebo\textsuperscript{15}.

**Myocardial infarction**

Over 20 years after the ‘Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction’ (DIGAMI) study, evidence for the necessity of tight glycaemic control in the immediate aftermath of AMI remains debatable\textsuperscript{40}. The DIGAMI study was primarily a trial of glucose-insulin-potassium (GIK) rather than glycaemic control and was predicated by the ideas that GIK may ameliorate platelet aggregation, reduce transmembrane excitability and therefore arrhythmias, and facilitate a switch in myocardial metabolism away from oxygen-dependent fatty acid metabolism to carbohydrate metabolism. After the study, it could not be determined whether mortality benefit at one year was due to the immediate intravenous infusion of GIK, subsequent subcutaneous insulin, or both. It was hoped that the follow-up DIGAMI2 would answer this but unfortunately was underpowered, in part due to protocol violations between groups and advances in therapeutic use of aspirin and statins\textsuperscript{41}. This results in a quandary as to glycaemic management after AMI. However, GLP-1 RA have properties, in addition to glucose lowering, that make them attractive for use in the immediate aftermath of AMI. The GLP-1 receptor is expressed in the heart\textsuperscript{42}, and exendin-4 directly activates cardiomyocyte signalling pathways\textsuperscript{43} which raises the possibility they may act directly on the cardiac muscle to improve ventricular ejection fraction and cardiac index\textsuperscript{16}. GLP-1 RA may also have an effect on increasing myocardial reliance on glucose, rather than
fatty acid metabolism (thereby being more oxygen efficient), akin to that proposed for GIK, although this theory is contentious \(^{44-47}\). Altered myocardial metabolism has been reported with albiglutide. In a murine model, albiglutide reduced the myocardial infarct size in association with increased cardiac uptake and utilisation of glucose. Gene expression analysis indicated an upregulation of key glucose metabolism genes in the preserved myocardium post treatment \(^{48}\).

Intriguingly, GLP-1 RA has a direct effect on myocytes independent to its action via the GLP-1 receptor. Studies of isolated cardiomyocytes, from GLP-1 receptor knockout mice, have shown a robust response to lixisenatide on the contractility response \(^{49}\). Within the coronary vessels themselves, human recombinant GLP-1 (7–36) amide - the cleavage product of GLP-1 (1-36) - exerts a beneficial effect on endothelial function \(^{50,51}\). In coronary endothelial cells taken from subjects with T2D, Exendin-4 could augment endothelial nitric oxide synthase (eNOS) phosphorylation and nitric oxide (NO) production \(^{52}\) – pathways that are known to lead to vascular relaxation \(^{53}\). Glucagon-like peptide 1 [7-36 amide]\(^{54}\) and liraglutide\(^{55}\) can exert a protective effect against endothelial dysfunction induced by hyperglycaemia and/or inflammation through a reduction of tumour necrosis factor-\(\alpha\) (TNF-\(\alpha\))-induced nuclear factor-\(\kappa\)B activation. This can decrease inflammatory gene expression, including vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 \(^{56}\). These properties have made GLP-1 RAs an attractive treatment option for patients with acute coronary ischaemia, as was suggested from a number of animal models \(^{57-60}\). In ten human subjects with left ventricular (LV) dysfunction, a 72-h infusion of GLP-1 (7–36) amide (1.5 pmol/kg/min), commenced after primary coronary angioplasty for acute myocardial infarction resulted in improved global and regional LV wall motion scores and reduced hospital stay (6.1 ± 1.3 days) vs 9.8 ± 1.5 days in controls \(^{61}\). There followed three
publications by a group in Copenhagen, from a larger RCT (n=172) comprised of patients with ST elevation myocardial infarction (STEMI) treated with exenatide\textsuperscript{9-11}, both with and without diabetes. Improvements in infarct size were seen, but no mortality benefit, when administered intravenously during primary percutaneous coronary intervention (PCI)\textsuperscript{9 10}. Since then, most\textsuperscript{11 62-64}, but not all\textsuperscript{65} trials have reported an effect of reducing coronary infarct size. Differences in glycaemic control achieved by the intervention may go towards explaining the difference. The protocol used by the Copenhagen group\textsuperscript{9-11} comprised exenatide or placebo given intravenously 15 min prior to intervention and continued six hours post-PCI—at which time blood glucose was 8.0 mmol/L in controls and 6.3 mmol/L with exenatide. Conversely in a study by Roos\textit{et al}\textsuperscript{65 66}, exenatide was administered for 72-hours after primary angioplasty in 91 individuals, with blood glucose measured every three-hours on day one, reduced to four-times per day thereafter; there were no differences in the number of hypoglycaemic episodes (considered <4 mmol/L [10 events in exenatide vs 9 in placebo; \(P=0.530\)]) or hyperglycaemic episodes (considered >10 mmol/L [3 events in exenatide vs 10 in placebo; \(P=0.064\)]).

The use of GLP-1 RA in non-ST elevation myocardial infarction (nSTEMI) was examined in a study of 90 patients randomized to liraglutide (0.6 mg for two days, 1.2 mg for two days, followed by 1.8 mg for three days) or placebo for seven days, liraglutide improved left ventricular ejection fraction by 4.7\% more than placebo after three-months\textsuperscript{67}. However, this seems a modest improvement and may not translate into measurable clinical outcomes. A significant improvement has been defined as an increase in the ejection fraction of \(\geq 8\%\) (which is two times the inter-observer variability with echocardiography)\textsuperscript{68}.

Is it feasible to achieve rapid normalisation of glucose after myocardial infarction with GLP-1? This was addressed in a study of 40 patients admitted to a CCU with hyperglycaemia ranging from 7.8 to 22.2 mmol/L\textsuperscript{69}. Patients received intravenous exenatide as a bolus
followed by a fixed dose infusion for up to 48 hours. Exenatide effectiveness was benchmarked to historical controls treated with insulin infusions. There was no difference in performance in the attainment of a target glucose range of 5.6-7.8 mmol/L although exenatide was discontinued in three patients after failure to achieve glycaemic control. Control was achieved without any episodes of severe hypoglycaemia (<2.8 mmol/L) although nausea (occurring in 16 patients) was problematic. By far the largest trial to date has been the Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) study. This randomised 6068 patients within 180 days of a cardiovascular event that required hospitalization. Once-daily subcutaneous injection of 20 mcg lixisenatide, as an add-on therapy to background antidiabetic medications, for 25 months was non-inferior to placebo for the composite occurrence of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina or heart failure, and revascularization. This study provided data for cardiovascular safety of lixisenatide but no advantage. The six-month window from cardiovascular event to recruitment does however, make it distinct from the trials described.

Cardiac surgery

Peri-operative glucose control reduces the incidence of sepsis and mediastinitis after cardiothoracic surgery. Van den Berghe’s 2001 paper, reporting improved post-operative outcomes with tight glycaemic control after (predominantly cardiovascular) surgery, continues to be hotly debated as the findings have not been replicated in multicentre trials. There is an increased likelihood of hypoglycaemia from the intensification of glucose targets with insulin therapy, which leads to worse outcomes. GLP-1 therapy offers the prospect of glycaemic control with less likelihood of hypoglycaemia after coronary surgery which may tip the balance in favour of tighter glycaemia targets when using this drug. The perioperative administration of exenatide (1.2-1.5 pmol/kg/min) has proved to be...
effective at improving glucose levels in patients with diabetes and stress hyperglycaemia undergoing cardiac surgery and can reduce peri-operative insulin requirements \(^{79-81}\), although reduction in hypoglycaemia was not always observed \(^{80}\). One trial in subjects with type 2 diabetes used a much higher infusion rate (3.6 pmol/kg/min) for 12 hours after transfer from the operating room to the intensive care unit (ICU) \(^{82}\) combined with insulin as a rescue medication if glucose concentrations were >7.8 mmol/L, for over three hours. The AUC for plasma glucose was no different between controls (receiving insulin alone) and exenatide.

Compared to patients receiving intravenous insulin, a lesser insulin requirement, with fewer dose adjustments, was necessary in the GLP-1 group over the first six hours.

In a small study of 20 patients with coronary heart disease and preserved left ventricular function who underwent CABG, use of GLP-1 [7-36 amide] as a continuous infusion beginning 12 hours before CABG and continuing for 48 hours resulted in less requirement for inotropic support— even in patients without diabetes \(^{83}\). However, no improvement in echocardiographic features of left ventricular dysfunction was seen in this study, or in a similarly executed study of perioperative intravenous exenatide with cardiothoracic surgery \(^{81}\) \(^{83}\). These postoperative trial outcomes corroborate the findings post MI suggesting little role for exogenous GLP-1 to improve cardiac performance acutely.

The ‘GLP-1 for bridging of hyperglycaemia during cardiac surgery’ (GLOBE) study is a large randomised parallel placebo-controlled trial, currently underway, with the intention of recruiting 274 patients undergoing cardiac surgery, with or without diabetes mellitus \(^{84}\). Patients will receive 0.6 mg liraglutide or placebo the evening before; and 1.2 mg liraglutide or placebo just prior to surgery. The primary endpoint is intra-operative insulin requirement: a relevant outcome as greater insulin infusion rates are associated with adverse clinical sequelae \(^{73}\) \(^{85}\). Taken together, these studies suggest that peri-operative GLP-1 helps to
achieve glycaemic control, with a lessened requirement for insulin. Further evidence is required whether this translates into fewer hypoglycaemic episodes. The immediate haemodynamic benefits are unproven.

**General surgery**

Less work has been undertaken in non-cardiac surgery. In a proof-of-concept study, eight patients with type 2 diabetes who had undergone major surgical procedures, were studied with a cross-over design, between the second and the eighth postoperative day. Patients received intravenous GLP-1 (7–36) amide (1.2 pmol/kg/min) or placebo over eight hours, each administered in randomized order in the fasting state. From a fasting glucose of 10mmol/L, infusion of GLP-1, lowered plasma glucose concentration to target (<7mmol/L) within 150 mins, whereas glucose remained above target throughout the 8-hour placebo infusion ($P<0.001$). Rapid attainment of normoglycaemia in the postoperative period makes GLP-1 an attractive option. Data are needed as to the efficacy of simple subcutaneous regimes.

For patients undergoing hip surgery, perioperative hyperglycaemia is associated with coagulation activation and an increased risk of venous thromboembolism. The effect of liraglutide on markers of coagulation has been tested in obese adults without diabetes, over the first three days after hip surgery. Despite improvement in median glucose (5.5mmol/L vs. 5.8 mmol/L with placebo; $P = 0.04$) there was negligible change in the markers of coagulation activation. Overall, there are few data to support the specific indication of GLP-1 RA use with general surgery.
Intensive care unit

The challenge of maintaining blood glucose between the hazards of hyper- and hypoglycaemia is equally true in ICU as it is with peri-operative patients. Tight glycaemic control (4.4–6.1 mmol/L) significantly increases the risk for hypoglycaemia, which can lead to poor outcomes. The administration of GLP-1 (7–36) amide has been tested for its glucopaenic action at the time of ICU admission. In a parallel-design RCT, 72-hr infusion of GLP-1 did not reduce intravenous insulin requirement nor the rate of hypoglycaemia compared to saline control, although there was less plasma glucose variability with GLP-1. Low glucose variability is protective in ICU patients, even when mean glucose levels are elevated, making this a potential attribute of GLP-1 therapy in the ICU environment.

Of note, this study did not control for the routes or quantity of nutritional support. An open-label RCT in India evaluated the effect of commencing fixed-dose liraglutide (1.2 mg) from the time of ICU admission: in a study population of 120 individuals, 46 were considered to have pre-existing T2DM and another 53 stress-hyperglycaemia. Intravenous insulin infusion was also used as required. Liraglutide reduced hypoglycaemia frequency and the variation of capillary glucose but with no difference in mean capillary glucose. An intriguing line of inquiry is whether GLP-1 can also ameliorate ICU catabolism. Critically ill patients in ICU suffer significant muscle loss. This worsens ICU mortality but also leads to debilitating weakness in those surviving to ICU discharge. Hyperglucagonaemia is thought to be a key factor to provoke catabolism and hyperglycaemia in critical illness. Given that a core attribute of GLP-1 is to suppress glucagon release from pancreatic alpha-cells, GLP-1 has theoretical anti-catabolic action as well as being effective in ameliorating stress hyperglycaemia.
A further challenge in prolonged critical illness is to maintain normoglycaemia in the setting of enteral and parenteral feeding protocols. A number of mechanistic studies from a group in Adelaide, Australia have shown that an infusion of GLP-1-(7–36) amide at 1.2 pmol/kg/min attenuates, but not abolishes, the glycaemic response to enteral nutrition in critically ill patients with stress hyperglycaemia and with type 2 diabetes. Slowing of gastric emptying appears to contribute to the glucose-lowering effect of exogenous GLP-1 in critically ill patients following a 100ml intra-gastric 'meal'. However, delayed gastric emptying is common in the critically ill and may occur in up to half of all ventilated patients. This may limit the magnitude of glycaemic control that could be achieved with GLP-1 RA during enteral feeding. Even so, there may be the potential for benefit even in patients fed parenterally. In a cross-over study of nine critically ill patients fed with parenteral nutrition consisting of glucose (3.2 ± 1.4 mg/kg/min), amino acids (n=8; 0.9 ± 0.2 mg/kg/min), with or without lipid emulsions, four hours infusion of GLP-1-(7–36) amide lowered glucose from 11.7 ± 1.3 mmol/L (with placebo) to 8.8 ± 1.4 mmol/L (P<0.001). Nausea is often encountered with GLP-1 RA but may be less of a concern in sedated patients receiving small intestinal feeding. Further issues to contend with in critical illness are kidney failure; pancreatitis; and the use of vasoactive drugs (including catecholamines) leading to a counter-regulatory hormonal response.

Conclusion
GLP-1 RA have a number of properties in addition to glucose lowering, which could be advantageous when started in an acute, hospitalised setting. However, there are few trial data in human subjects to support their adoption in routine clinical practice in this environment. The increasing use of GLP-1 RA in outpatients will mean that patients using these
medications will become increasingly seen in acute settings. Trials are needed to establish their place in acute illness.

References

1. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol* 2018;6(2):105-13. doi: 10.1016/S2213-8587(17)30412-6
2. Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes Metab Syndr Obes* 2017;10:123-39. doi: 10.2147/DMSO.S130834
3. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2018;61(12):2461-98. doi: 10.1007/s00125-018-4729-5
4. Joint British Diabetes Societies for inpatient care. Management of adults with diabetes undergoing surgery and elective procedures: improving standards. 2016 https://abcd.care/sites/abcd.care/files/resources/Surgical_guidelines_2015_full_FINAL_amended_Mar_2016.pdf Accessed April 2019.
5. American Diabetes A. 14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018;41(Suppl 1):S144-S51. doi: 10.2337/dc18-S014
6. Diabetes Canada Clinical Practice Guidelines Expert C, Malcolm J, Halperin I, et al. In-Hospital Management of Diabetes. *Can J Diabetes* 2018;42 Suppl 1:S115-S23. doi: 10.1016/j.jcjd.2017.10.014
7. Daly SC, Chemmanam T, Loh PS, et al. Exenatide in acute ischemic stroke. *Int J Stroke* 2013;8(7):E44. doi: 10.1111/ijs.12073
8. Galiatsatos P, Gibson BR, Rabiee A, et al. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. *Crit Care Med* 2014;42(3):638-45. doi: 10.1097/CCM.000000000000035
9. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. *Circ Cardiovasc Interv* 2012;5(2):288-95. doi: 10.1161/CIRCINTERVENTIONS.112.968388
10. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. *Eur Heart J* 2012;33(12):1491-9. doi: 10.1093/eurheartj/ehr309
11. Lonborg J, Vejlstrup N, Kelbaek H, et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study. *Diabetes* 2014;63(7):2474-85. doi: 10.2337/db13-1849
12. McGrath RT, Hocking SL, Priglinger M, et al. Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study. *BMJ Open* 2016;6(2):e008203. doi: 10.1136/bmjopen-2015-008203
13. Muller C, Cheung NW, Dewey H, et al. Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study.
of exenatide vs. standard care in post stroke hyperglycemia. *Int J Stroke* 2018;1747493018784436. doi: 10.1177/1747493018784436

14. Wiberg S, Hassager C, Schmidt H, et al. Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial. *Circulation* 2016;134(25):2115-24. doi: 10.1161/CIRCULATIONAHA.116.024088

15. Wiberg S, Kjaergaard J, Schmidt H, et al. The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest. *Crit Care Med* 2018;46(2):e118-e25. doi: 10.1097/CCM.0000000000002814

16. Wroge J, Williams NT. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. *Ann Pharmacother* 2016;50(12):1041-50. doi: 10.1177/1060028016663218

17. Zweck E, Roden M. GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects? *Lancet Diabetes Endocrinol* 2019;7(2):89-90. doi: 10.1016/S2213-8587(18)30351-6

18. Patel KS, Carroll R. Hormonal Management of Small Bowel Failure. *Clin Transl Gastroenterol* 2017;8(6):e105. doi: 10.1038/ctg.2017.32

19. Baird TA, Parsons MW, Phan T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. *Stroke* 2003;34(9):2208-14. doi: 10.1161/01.STR.0000085087.41330.FF

20. Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. *Stroke* 2004;35(2):363-4. doi: 10.1161/01.STR.0000115297.92132.84

21. Baker L, Juneja R, Bruno A. Management of hyperglycemia in acute ischemic stroke. *Curr Treat Options Neurol* 2011;13(6):616-28. doi: 10.1007/s11940-011-0143-8

22. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke* 2001;32(10):2426-32.

23. Matz K, Keresztes K, Tatschl C, et al. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. *Diabetes Care* 2006;29(4):792-7.

24. Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. *Cochrane Database Syst Rev* 2014(1):CD005346. doi: 10.1002/14651858.CD005346.pub4

25. Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. *Stroke* 2008;39(2):384-9. doi: 10.1161/STROKEAHA.107.493544

26. Gray CS, Hildreth AJ, Sandercocck PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). *Lancet Neurol* 2007;6(5):397-406. doi: 10.1016/S1474-4422(07)70080-7

27. McCormick M, Hadley D, McLean JR, et al. Randomized, controlled trial of insulin for acute poststroke hyperglycemia. *Ann Neurol* 2010;67(5):570-8. doi: 10.1002/ana.21983

28. Bilotta F, Caramia R, Cernak I, et al. Intensive insulin therapy after severe traumatic brain injury: a randomized clinical trial. *Neurocrit Care* 2008;9(2):159-66. doi: 10.1007/s12028-008-9084-9

29. Bilotta F, Caramia R, Paoloni FP, et al. Safety and efficacy of intensive insulin therapy in critical neurological patients. *Anesthesiology* 2009;110(3):611-9. doi: 10.1097/ALN.0b013e318198004b

30. Bilotta F, Spinelli A, Giovannini F, et al. The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome, and mortality in neurointensive care
unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a randomized prospective pilot trial. J Neurosurg Anesthesiol 2007;19(3):156-60. doi: 10.1097/ANA.0b013e3180338e69

31. Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care 2013;36(4):894-900. doi: 10.2337/dc12-0916

32. Ntaios G, Egli M, Faouzi M, et al. J-shaped association between serum glucose and functional outcome in acute ischemic stroke. Stroke 2010;41(10):2366-70. doi: 10.1161/STROKEAHA.110.592170

33. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117(2):77-88.

34. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003;27(3):313-8. doi: 10.1038/sj.iibo.0802206

35. McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630(1-3):158-62. doi: 10.1016/j.ejphar.2009.12.023

36. Darsalia V, Mansouri S, Ortsater H, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 2012;122(10):73-83. doi: 10.1042/CS2110374

37. Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011;31(8):1696-705. doi: 10.1038/jcbfm.2011.51

38. Stammert P, Collignon O, Hassager C, et al. Neuron-Specific Enolase as a Predictor of Death or Poor Neurological Outcome After Out-of-Hospital Cardiac Arrest and Targeted Temperature Management at 33 degrees C and 36 degrees C. J Am Coll Cardiol 2015;65(19):2104-14. doi: 10.1016/j.jacc.2015.03.538

39. Donnino MW, Andersen LW, Giberson T, et al. Initial lactate and lactate change in post-cardiac arrest: a multicenter validation study. Crit Care Med 2014;42(8):1804-11. doi: 10.1097/CCM.0000000000000332

40. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26(1):57-65.

41. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26(7):650-61. doi: 10.1093/eurheartj/ehi199

42. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and -independent pathways. Circulation 2008;117(18):2340-50. doi: 10.1161/CIRCULATIONAHA.107.739938

43. Vila Petroff MG, Egan JM, Wang X, et al. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001;89(5):445-52.

44. Gejl M, Lerche S, Mengel A, et al. Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia. PLoS One 2014;9(1):e83758. doi: 10.1371/journal.pone.0083758

45. Gejl M, Søndergaard HM, Stecher C, et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in
patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97(7):E1165-9. doi: 10.1210/jc.2011-3456

46. Hansen J, Brock B, Botker HE, et al. Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. Rev Endocr Metab Disord 2014;15(3):219-31. doi: 10.1007/s11154-014-9286-8

47. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289(6):H2401-8. doi: 10.1152/ajpheart.00347.2005

48. Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570

49. Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 2013;11:84. doi: 10.1186/1479-5876-11-84

50. Ishibashi Y, Matsui T, Takeuchi M, et al. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010;391(3):1405-8. doi: 10.1016/j.bbrc.2009.12.075

51. Oyama J, Higashi Y, Node K. Do incretins improve endothelial function? Cardiovasc Diabetol 2014;13:21. doi: 10.1186/1475-2840-13-21

52. Di Tomo P, Lanuti P, Di Pietro N, et al. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146(1-3):243-9. doi: 10.1016/jрегеп.2007.10.001

This article is protected by copyright. All rights reserved.
60. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. *J Am Coll Cardiol* 2009;53(6):501-10. doi: 10.1016/j.jacc.2008.10.033

61. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. *Circulation* 2004;109(8):962-5. doi: 10.1161/01.CIR.0000012505.91348.58

62. Chen WR, Chen YD, Tian F, et al. Effects of liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction. *Circ Cardiovasc Imaging* 2016;9(12) doi: 10.1161/CIRCIMAGING.116.005146

63. DeNicola M, Du J, Wang Z, et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. *Am J Physiol Endocrinol Metab* 2014;307(8):E630-43. doi: 10.1152/ajpendo.00109.2014

64. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. *Arterioscler Thromb Vase Biol* 2013;33(9):2252-60. doi: 10.1161/ATVBAHA.113.301586

65. Roos ST, Timmers L, Biesbroek PS, et al. No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. *Int J Cardiol* 2016;220:809-14. doi: 10.1016/j.ijcard.2016.06.283

66. Scholte M, Timmers L, Bernink FJ, et al. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. *Trials* 2011;12:240. doi: 10.1186/1745-6215-12-240

67. Chen WR, Shen XQ, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. *Endocrine* 2016;52(3):516-26. doi: 10.1007/s12020-015-0798-0

68. Joshi K, Alam I, Ruden E, et al. Effect of improvement in left ventricular ejection fraction on long-term survival in revascularized patients with ischaemic left ventricular systolic dysfunction. *Eur J Echocardiogr* 2011;12(6):454-60. doi: 10.1093/ejechocard/jer045

69. Abuanaddi M, Kosiborod M, Riggs L, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. *Endocr Pract* 2013;19(1):81-90. doi: 10.4158/EP12196.OR

70. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med* 2015;373(23):2247-57. doi: 10.1056/NEJMoa1509225

71. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2003;125(5):1007-21. doi: 10.1067/mct.2003.181

72. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. *Endocr Pract* 2004;10 Suppl 2:21-33. doi: 10.4158/EP.10.S2.21

73. van den Berge H, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345(19):1359-67. doi: 10.1056/NEJMoa011300

74. Brunekhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008;358(2):125-39. doi: 10.1056/NEJMoa070716
75. Gunst J, De Bruyn A, Van den Berghe G. Glucose control in the ICU. *Curr Opin Anaesthesiol* 2019 doi: 10.1097/ACO.0000000000000706

76. Investigators N-SS, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360(13):1283-97. doi: 10.1056/NEJMoa0810625

77. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med* 2009;35(10):1738-48. doi: 10.1007/s00134-009-1585-2

78. Johnston LE, Kirby JL, Downs EA, et al. Postoperative Hypoglycemia Is Associated With Worse Outcomes After Cardiac Operations. *Ann Thorac Surg* 2017;103(2):526-32. doi: 10.1016/j.athoracsur.2016.05.121

79. Besch G, Perrotti A, Mauny F, et al. Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery: A Phase II/III Randomized Trial. *Anesthesiology* 2017;127(5):775-87. doi: 10.1097/ALN.0000000000001838

80. Kohl BA, Hammond MS, Cucchiara AJ, et al. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study. *J Cardiothorac Vasc Anesth* 2014;28(3):618-25. doi: 10.1053/j.jvca.2013.06.021

81. Lips M, Mraz M, Klouckova J, et al. Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial. *Diabetes Obes Metab* 2017;19(12):1818-22. doi: 10.1111/dom.13029

82. Mussig K, Oncu A, Lindauer P, et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. *Am J Cardiol* 2008;102(5):646-7. doi: 10.1016/j.amjcard.2008.06.029

83. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. *Am J Cardiol* 2007;100(5):824-9. doi: 10.1016/j.amjcard.2007.05.2041

84. Hulst AH, Visscher MJ, Godfried MB, et al. Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery. *BMJ Open* 2018;8(6):e022189. doi: 10.1136/bmjopen-2018-022189

85. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. *JAMA* 2003;290(15):2041-7. doi: 10.1001/jama.290.15.2041

86. Meier JJ, Weyhe D, Michaely M, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. *Crit Care Med* 2004;32(3):848-51.

87. Lemkes BA, Hermanides J, Devries JH, et al. Hyperglycemia: a prothrombotic factor? *J Thromb Haemost* 2010;8(8):1663-9. doi: 10.1111/j.1538-7836.2010.03910.x

88. Sechterberger MK, Hermanides J, Poolman RW, et al. Lowering blood glucose during hip surgery does not influence coagulation activation. *BBA Clin* 2015;3:227-32. doi: 10.1016/j.bbalci.2015.03.001

89. Hermanides J, Vriesendorp TM, Bosman RJ, et al. Glucose variability is associated with intensive care unit mortality. *Crit Care Med* 2010;38(3):838-42. doi: 10.1097/CCM.0b013e3181cc4be9
90. Verma V, Kotwal N, Upreti V, et al. Liraglutide as an Alternative to Insulin for Glycemic Control in Intensive Care Unit: A Randomized, Open-label, Clinical Study. Indian J Crit Care Med 2017;21(9):568-72. doi: 10.4103/ijccm.IJCCM_105_17
91. Wischmeyer PE, Puthucheary Z, San Millan I, et al. Muscle mass and physical recovery in ICU: innovations for targeting of nutrition and exercise. Curr Opin Crit Care 2017;23(4):269-78. doi: 10.1097/MCC.0000000000000431
92. Harp JB, Yancopoulos GD, Gromada J. Glucagon orchestrates stress-induced hyperglycaemia. Diabetes Obes Metab 2016;18(7):648-53. doi: 10.1111/dom.12668
93. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004;30(5):748-56. doi: 10.1007/s00134-004-2167-y
94. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005;128(2):135-48. doi: 10.1016/j.regpep.2004.07.014
95. Deane AM, Chapman MJ, Fraser RJ, et al. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009;13(3):R67. doi: 10.1186/cc7874
96. Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycaemia. Crit Care Med 2010;38(5):1261-9. doi: 10.1097/CCM.0b013e3181d9d87a
97. Deane AM, Summers MJ, Zaknic AV, et al. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 2011;15(1):R35. doi: 10.1186/cc9983
98. Deane A, Chapman MJ, Fraser RJ, et al. Mechanisms underlying feed intolerance in the critically ill: implications for treatment. World J Gastroenterol 2007;13(29):3909-17.
99. Nauck MA, Walberg J, Vethacke A, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004;118(1-2):89-97. doi: 10.1016/j.regpep.2003.11.003

MBW and OGM jointly wrote the manuscript. All authors have read and approved the final manuscript.

This article is protected by copyright. All rights reserved.